Bevacizumab Combination Therapy Versus Standard Chemotherapy for Ovarian Cancer in Shorter and Longer Follow-Up Duration: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Obaid Ur RehmanEeshal FatimaHiba ImranUmar AkramAmna Badar AhmadZain Ali NadeemLaveeza FatimaAhmad HussainManar Alaa MabroukMuhammad Zain FarooqPublished in: American journal of clinical oncology (2024)
Bevacizumab may improve progression-free survival within and after 36 months, overall survival within 36 months, and reduce disease progression within 36 months.